ASH 2018 Annual Meeting Highlights in Multiple Myeloma
Release Date: December 21, 2018
Expiration Date: December 21, 2019
Expected time to complete this activity as designed: 60 minutes
There are no fees for participating in or receiving credit for this online activity.
In this activity, key opinion leaders present important highlights of several significant scientific updates in multiple myeloma (MM) presented at the 2018 American Society of Hematology (ASH) Annual Meeting. In this activity, you can view videos from the meeting and listen as they share their insights on a variety of abstracts covering topics including, but not limited to: the impact of early vs. late relapse in response to carfilzomib; novel treatment options for penta-refractory MM; CAR T-cell therapy; once-weekly vs. twice-weekly carfilzomib plus dexamethasone; venetoclax plus carfilzomib and dexamethasone in patients with RRMM; and maintenance therapy with ixazomib.
This activity is designed for multidisciplinary healthcare providers in the community setting, including hematologists, oncologists, nurses, pharmacists and other allied healthcare professionals who provide care to patients with multiple myeloma.
Upon completion of this educational activity, participants should be able to:
- Summarize the efficacy and safety data from clinical trials investigating novel therapies and treatment strategies in patients with multiple myeloma (MM)
- Describe expert faculty perspectives on key clinical trial data for novel therapies and treatment strategies in MM
- Recognize the potential impact of clinical trials on clinical practice and existing treatment paradigms in MM
- KCRD vs. CTD/CRD Induction Therapy Prior to ASCT – Faith Davies, MD, MBBCh, MRCP, FRCPath
- Ixazomib Prolongs PFS Following ASCT in Patients with NDMM: Phase 3 Tourmaline-MM3 Trial – Meletios A. Dimopoulos, MD
- Once vs. Twice Weekly Carfilzomib Dosing in Patients with RRMM: Phase 3 A.R.R.O.W Study – Meletios A. Dimopoulos, MD
- Isatuximab as a Single Agent and in Combination with Dexamethasone in RRMM – Meletios A. Dimopoulos, MD
- Phase 2 Study of Venetoclax Plus Carfilzomib and Dexamethasone in Patients with RRMM – Shaji K. Kumar, MD
- Phase 2 Trial of Ixazomib, Lenalidomide, Dexamethasone and Daratumumab in Patients with NDMM – Shaji K. Kumar, MD
- Carfilzomib in RRMM Patients with Early or Late Relapse Following Prior Therapy – María-Victoria Mateos, MD, PhD
- Efficacy and Safety of Once-Weekly vs Twice-Weekly Carfilzomib Plus Dexamethasone – María-Victoria Mateos, MD, PhD
- Anti-BCMA CAR T-cell Therapy for RRMM – Philip L. McCarthy, MD
- Initial Results from a Phase 1 Clinical Study of bb21217 – Noopur Raje, MD
- Updated Analysis of LCAR-B38M in Patients with RRMM – Noopur Raje, MD
- Selinexor Plus Low Dose Dexamethasone in Patients with Penta-Refractory MM – Dan T. Vogl, MD, MSCE
Instructions for Participation and Credit
This activity is eligible for credit through December 21, 2019. After this date, this activity will expire and no further credit will be awarded.
- Read the target audience, learning objectives, and faculty disclosures.
- You may be asked to complete a short pre-test before accessing the educational content. This must be completed in order to move forward in the activity.
- Complete the educational content as designed.
- Complete the post-test. To receive a certificate, you must receive a passing score of 70%.
- Complete the activity evaluation survey to provide feedback and information useful for future programming.
- Certificates for CME and CNE may be printed immediately after successfully completing the post-test and activity evaluation. Pharmacist credit will be uploaded to CPE Monitor 4 weeks following receipt of a completed, qualified form.
Faith Davies, MD, MBBCh, MRCP, FRCPath
Professor of Medicine
University of Arkansas for Medical Sciences
Little Rock, Arkansas
Dr. Faith Davies earned her medical degree from the University of Wales College of Medicine and completed her general medical training and hematology specialty training in the United Kingdom. She then held positions with the Institute of Cancer Research and the Royal Marsden Hospital, both in London, prior to moving to the USA. Dr. Davies is a Professor of Medicine of the Myeloma Center at the University of Arkansas for Medical Sciences in Little Rock, Arkansas.
Dr. Davies is a member of the American Society of Hematology, the American Association for Cancer Research, the Royal College of Physicians (UK), and the Royal College of Pathologists (UK). She is widely published in The New England Journal of Medicine, Blood, Journal of Clinical Oncology, Leukemia, and The Lancet Oncology, among others. Her clinical research focuses on the treatment of multiple myeloma, particularly the investigation of new drugs and genetic technologies to improve patient outcomes. Her laboratory work is aimed at identifying biologically based therapeutic targets in myeloma that are amenable to small-molecule interventions and translating those laboratory findings into the clinical arena to provide individualized treatment.
Meletios A. Dimopoulos, MD
Professor and Chairman
Department of Clinical Therapeutics
National and Kapodistrian University of Athens School of Medicine
Dr. Meletios Dimopoulos received his medical degree from the National and Kapodistrian University of Athens, Greece. He completed a residency in internal medicine at the Royal Victoria Hospital, McGill University, Montreal, Canada, and a fellowship in hematology/oncology at the University of Texas MD Anderson Cancer Center, Houston. Dr. Dimopoulos is Professor and Chairman of the Department of Clinical Therapeutics at the National and Kapodistrian University of Athens School of Medicine; he was also elected dean of the medical school and rector of the university.
Currently, Dr. Dimopoulos is the chairman of the Greek Myeloma Study Group and of the Balkan Myeloma Study Group. He serves on the scientific advisory boards of the International Myeloma Foundation and the International Waldenström’s Macroglobulinemia Foundation, and is a board member of the European Myeloma Network. He has authored more than 931 publications in peer-reviewed journals, as well as numerous abstracts and several textbook chapters primarily focusing on plasma cell dyscrasias, and genitourinary and gynecologic cancers. In addition, Dr. Dimopoulos is a journal reviewer for The New England Journal of Medicine, Blood, Journal of Clinical Oncology, Haematologica, Leukemia, Cancer, European Journal of Haematology, and Leukemia and Lymphoma. He is also associate editor of Current Hematologic Malignancy Reports, and is an editorial board member of Haematologica, Leukemia and Lymphoma, Clinical Lymphoma and Myeloma, Expert Review of Hematology and Blood Advances.
Dr. Dimopoulos is a recent recipient of Waldenström’s award for Myeloma Research of the International Myeloma Society and the CoMy Excellence Award. In May 2018 he was elected as foreign associate member of the National Academy of Medicine of France.
Shaji K. Kumar, MD
Professor of Medicine
Mayo Clinic College of Medicine
Consultant, Division of Hematology
Medical Director, Cancer Clinical Research Office
Dr. Shaji Kumar received his medical degree from All India Institute of Medical Sciences in New Delhi, India. His postdoctoral training included a residency in internal medicine from the All India Institute of Medical Sciences, followed by a residency in internal medicine and a fellowship in hematology/oncology at the Mayo Graduate School of Medicine in Rochester, Minnesota. He is currently the Medical Director for the Cancer Center Clinical Research Office which oversees the development, activation, conduct, and monitoring of interventional trials across the three site Mayo Clinic Cancer Center.
Certified by the American Board of Internal Medicine (ABIM) in internal medicine, medical oncology, and an ABIM diplomate in hematology, Dr. Kumar holds membership in several professional organizations including the American Society of Hematology, American Society of Clinical Oncology, American Association for Cancer Research, American Society of Blood and Marrow Transplantation, the Association of Physicians of India, and the European Hematology Association. He has published numerous articles, abstracts, editorials, and letters in the peer-reviewed literature, including Blood, Journal of Clinical Oncology, Leukemia, American Journal of Hematology, British Journal of Haematology, and Bone Marrow Transplantation. He is also a member of the editorial board for several journals including American Journal of Hematology, European Journal of Clinical and Medical Oncology, and Leukemia.
Dr. Kumar’s research focuses on the development of novel drugs for the treatment of myeloma, and he has presented nationally and internationally. He is the principal investigator of several phase 1 and phase 2 clinical trials exploring new drugs and combinations for newly diagnosed and relapsed myeloma. His laboratory is focused on understanding the role of bone marrow microenvironment in the development and progression of myeloma.
María-Victoria Mateos, MD, PhD
Associate Professor of Medicine
University of Salamanca
Dr. María-Victoria Mateos received her medical degree from the University of Valladolid in Spain and completed her residency in hematology at the University Hospital of
Salamanca, where she also completed a doctoral degree. She is a consultant physician in the Hematology Department and Associate Professor of Medicine at the University of Salamanca, Spain. In addition, she is the Director of the Myeloma Program and coordinates the Clinical Trials Unit in Salamanca’s University Hospital Hematology Department.
Dr. Mateos is a member of the International Myeloma Working Group (IMWG), International Myeloma Society (IMS), and has served on the European Hematology Association(EHA) Scientific Program Committee and Advisory Board, and the American Society of Hematology(ASH) Scientific Committee on plasma cell diseases. She is a Councilor on the EHA Board, a member of the Steering Committee for the Society of Hematologic Oncology (SOHO), the International Myeloma Society(IMS) board, and the European School of Haematology (ESH) Scientific Committee. In addition, Dr. Mateos serves as coordinator of GEM (Spanish Myeloma Group), with direct involvement in the design and development of clinical trials. She has coordinated many clinical trials in elderly and smoldering multiple myeloma patients that have profoundly influenced current options for treating these patient populations.
Dr. Mateos has published more than 200 papers in peer-reviewed international journals, some of which have become key references in the multiple myeloma field. She is associate editor of myeloma in Annals of Haematology, and is a reviewer for journals such as The New England Journal of Medicine, Lancet, and Lancet Oncology.
Philip L. McCarthy, MD
Professor of Oncology
Director, Blood and Marrow Transplant Program
Roswell Park Cancer Institute
Buffalo, New York
Dr. Philip McCarthy received his medical degree from Tufts University School of Medicine, Boston, Massachusetts. He completed an internship and residency at Yale-New Haven Hospital, and hematology and medical oncology fellowship training at Brigham and Women's Hospital and Dana Farber Cancer Institute. Dr. McCarthy is Professor of Oncology and Director of the Blood and Marrow Transplant Program at Roswell Park Cancer Institute, Buffalo. He is also Professor of Internal Medicine at the State University of New York at Buffalo.
Dr. McCarthy is a diplomate, American Board of Internal Medicine, with subspecialty certification in medical oncology and hematology, and holds membership in the American Society of Hematology (ASH), American Society for Blood and Marrow Transplantation (ASBMT), American Society of Clinical Oncology (ASCO), American Association of Blood Banking (AABB), and the American Association for Cancer Research (AACR). He is associate chair of the Myeloma Committee of the Alliance for Clinical Trials in Oncology (ACTION) and a member of the Transplant Committee. He is an associate editor of the Biology of Blood and Marrow Transplantation journal, as well as an ad hoc reviewer for several journals including Blood, Bone Marrow Transplantation, Journal of Clinical Oncology, Haematologica, Leukemia and Lymphoma, and JNCCN. Dr. McCarthy has published more than 200 peer-reviewed manuscripts and reviews. His major research interests include blood and marrow transplantation, graft-versus-host disease/graft-versus-tumor effect, cancer immunotherapy, and multiple myeloma.
Noopur Raje, MD
Professor of Medicine
Harvard Medical School
Director, Center for Multiple Myeloma
Massachusetts General Hospital
Dr. Noopur Raje received her medical degree from B.J. Medical College, Pune University in India. She trained in internal medicine at Massachusetts General Hospital (MGH), and subsequently completed a fellowship in hematology and medical oncology in the joint Mass General-Brigham & Women’s-Dana-Farber program. She is a Professor of Medicine at Harvard Medical School and the Rita M. Kelley Chair in Oncology at MGH.
Dr. Raje is a physician scientist with a focus on the development of innovative therapies for multiple myeloma. As Director of the Center for Multiple Myeloma at the MGH Cancer Center, she leads a dedicated clinical team engaged in investigator-initiated, multicenter national and international clinical trials, all aimed at developing new promising therapies for this disease. She also leads translational efforts at MGH with her laboratory's efforts focused on identifying cellular signaling pathways that contribute to the survival and proliferation of myeloma cells in the bone environment, and whose targeting may result in improved therapeutic outcomes. Dr. Raje is the recipient of numerous awards including the Multiple Myeloma Senior Research Award, The Leukemia and Lymphoma Society Clinical Scholar Award and the Claflin Distinguished Scholar Award.
Dan T. Vogl, MD, MSCE
Assistant Professor of Medicine
Division of Hematology/Oncology
Abramson Cancer Center
University of Pennsylvania
Dr. Dan Vogl received his medical degree from Weill Medical College of Cornell University in New York. He completed an internal medicine residency at Columbia-Presbyterian Medical Center, New York, and a hematology-oncology fellowship at the Hospital of the University of Pennsylvania, Philadelphia. Dr. Vogl also received a master of science degree in clinical epidemiology from the University of Pennsylvania School of Medicine. He is Assistant Professor of Medicine, Division of Hematology/Oncology, at the Abramson Cancer Center of the University of Pennsylvania.
Dr. Vogl’s clinical research focuses on novel therapies for multiple myeloma. Since 2015, Dr. Vogl has been Medical Director of the Abramson Cancer Center’s Clinical Research Unit, overseeing the work of over 90 research nurses, research coordinators, regulatory coordinators, and biospecimen coordinators, who together manage almost 300 active cancer clinical trials.
Accreditation Statement: MediCom Worldwide, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation Statement: MediCom Worldwide, Inc. designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MediCom Worldwide, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This activity is acceptable for 1.0 contact hour of Continuing Education Credit. Universal Activity Number: 827-0000-18-054-H01-P. Knowledge-based CPE activity.
In order for CPE Monitor to authenticate credit, pharmacists/technicians must provide their e-Profile ID number from NABP and date of birth (in MMDD format) when claiming credit for a CPE program.
Accreditation Statement: MediCom Worldwide, Inc., 101 Washington Street, Morrisville, PA 19067 is approved by the California Board of Registered Nursing, Provider Number CEP11380. MediCom designates this CNE activity for 1.0 contact hour. Program Number: 18-054-092
As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE) and California State Board of Registered Nursing, MediCom Worldwide, Inc. requires everyone who is in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest. Accordingly, the following disclosures were made.
Dr. Faith Davies has received honoraria as a consultant from AbbVie Inc., Amgen Inc., Bristol-Myers Squibb Company, Celgene Corporation, Janssen Pharmaceuticals, Inc., and Takeda Oncology.
Dr. Meletios Dimopoulos has received honoraria as a consultant from Amgen Inc., Bristol-Myers Squibb Company, Celgene Corporation, Janssen Pharmaceuticals, Inc., and Takeda Oncology.
Dr. Shaji Kumar has received honoraria as a consultant from AbbVie Inc., Amgen Inc., Celgene Corporation, Genentech, Inc., Janssen Pharmaceuticals, Inc., Kite Pharma, MedImmune, LLC, Merck & Co., Inc., Oncopeptides AB, and Takeda Oncology. He has received grant support related to research activities from AbbVie, Amgen, Bristol-Myers Squibb Company, Celgene, Janssen, F. Hoffmann-La Roche Ltd, Genentech, Kite, MedImmune, Merck, Novartis AG, Sanofi, and Takeda.
Dr. María-Victoria Mateos has received honoraria related to formal advisory activities from AbbVie Inc., Amgen Inc., Celgene Corporation, GlaxoSmithKline plc, Janssen Pharmaceuticals, Inc., and Takeda Oncology.
Dr. Philip McCarthy has received honoraria as a consultant from Bristol-Myers Squibb Company, Celgene Corporation, Janssen Pharmaceuticals, Inc., Karyopharm Therapeutics, Sanofi, Takeda Oncology, and The Binding Site Ltd. He has received grant support related to research activities from Celgene.
Dr. Noopur Raje has received honoraria as a consultant from Amgen Inc., Celgene Corporation, Onyx Pharmaceuticals, Inc., an Amgen subsidiary, and Takeda Oncology.
Dr. Dan Vogl has received honoraria as a consultant from Amgen Inc., Celgene Corporation, Janssen Pharmaceuticals, Inc., Karyopharm Therapeutics, and Takeda Oncology.
Planning Committee Disclosures
The individuals listed below from MediCom Worldwide, Inc. reported the following for this activity: Kristin Burke, Project Manager, Joan Meyer, RN, MHA, Executive Director, and Bill Stoff, Director of Operations,have no relevant financial relationships.
Peer Reviewer Disclosure
In accordance with MediCom Worldwide, Inc. policy, all content is reviewed by external independent peer reviewers for balance, objectivity and commercial bias. The peer reviewers have no relevant financial relationships to disclose.
If you have any questions or concerns regarding this activity, please contact MediCom Worldwide, Inc. at 1-800-408-4242 or email us at email@example.com
Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Amgen, Inc., Bristol-Myers Squibb, Celgene Corporation, Takeda Oncology
©2018 MediCom Worldwide, Inc., 101 Washington St., Morrisville, PA 19067, 800-408-4242.
No portion of this material may be copied or duplicated without the expressed permission of MediCom Worldwide, Inc.